TP53 and head and neck cancer: In head and neck cancers, regardless of TP53 mutation status, combining WEE1 and Aurora kinase inhibitors leads to enhanced cell death over either agent alone because WEE1 inhibition triggers mitotic progression in cells with Alisertib induced spindle defects [38].